Immunovant, Inc. (IMVT) vs Ligand Pharmaceuticals Incorporated (LGND)
A side-by-side comparison of Immunovant, Inc. and Ligand Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMVT
Immunovant, Inc.
$31.44HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
LGND
Ligand Pharmaceuticals Incorporated
$294.61HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — IMVT vs LGND
growth of $100 · dividends reinvested · last 7yIMVT +234.2% (+18.8%/yr)LGND +330.4% (+23.2%/yr)LGND compounded faster over this window
IMVT LGND
IMVT vs LGND: by the numbers
- •IMVT is the larger company ($6.49B vs $5.90B market cap).
- •LGND is profitable (67.88% net margin) while IMVT runs a net loss (-7585.86%).
Metrics side by side
Valuation
| Metric | IMVT | LGND |
|---|---|---|
| P/E ratio | N/A | 31.51 |
| Forward P/E | N/A | 31.66 |
| P/S ratio | 914.74 | 20.32 |
| P/B ratio | 8.83 | 6.10 |
| EV / EBITDA | N/A | 44.67 |
| FCF yield | N/A | 2.22% |
Profitability
| Metric | IMVT | LGND |
|---|---|---|
| Gross margin | 0.00% | 98.58% |
| Operating margin | 0.00% | 17.61% |
| Net margin | -7585.86% | 67.88% |
| ROE | -73.19% | 20.38% |
| ROIC | -76.00% | 3.91% |
Growth (annualized)
| Metric | IMVT | LGND |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 2.92% |
| FCF CAGR (5Y) | N/A | -0.49% |
| Total return CAGR (5Y) | 29.93% | 30.72% |
Frequently asked
- Is IMVT or LGND more profitable?
- LGND runs the higher net margin — IMVT at -7585.86% versus LGND at 67.88%.
- How have IMVT and LGND total returns compared?
- Over the past 5 years, IMVT delivered 29.93% and LGND delivered 30.72% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Ligand Pharmaceuticals P/E ratioImmunovant ROELigand Pharmaceuticals ROEImmunovant operating marginLigand Pharmaceuticals operating marginImmunovant revenue growthLigand Pharmaceuticals revenue growthImmunovant free cash flowLigand Pharmaceuticals free cash flow
Immunovant & Ligand Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.